This site is intended for Healthcare Professionals only

Xultophy: new diabetes drug

Clinical bookmark icon off

Xultophy: new diabetes drug

The EC has granted marketing authorisation for Xultophy, which combines once-daily basal insulin degludec and a GLP-1 receptor agonist (liraglutide) in one pen for adults with type 2 diabetes.

Xultophy is added to oral hypoglycaemics when the latter (alone or with basal insulin) do not provide adequate control

Copy Link copy link button

Clinical

Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.

Share: